10x Genomics, Inc. (TXG) Bundle
Who Invests in 10x Genomics, Inc. (TXG) and Why?
Investor Profile Analysis for Precision Genomics Technology Company
Key Investor Types Breakdown
| Investor Category | Percentage Ownership | Total Investment Value |
|---|---|---|
| Institutional Investors | 87.4% | $2.3 billion |
| Retail Investors | 12.6% | $332 million |
Top Institutional Investors
- Vanguard Group: 8.2% ownership
- BlackRock: 7.5% ownership
- Fidelity Management: 6.3% ownership
- Capital World Investors: 5.9% ownership
Investment Motivations
Investors are attracted by:
- Market potential in genomic technologies
- Strong research and development pipeline
- Potential for breakthrough scientific innovations
Investor Strategy Composition
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-term Hold | 68% |
| Growth Investment | 22% |
| Short-term Trading | 10% |
Financial Performance Metrics
Current stock valuation: $45.67 per share
Market capitalization: $6.8 billion
Annual revenue: $579 million
Institutional Ownership and Major Shareholders of 10x Genomics, Inc. (TXG)
Investor Profile Analysis for Precision Genomics Technology Company
Key Investor Types Breakdown
| Investor Category | Percentage Ownership | Total Investment Value |
|---|---|---|
| Institutional Investors | 87.4% | $2.3 billion |
| Retail Investors | 12.6% | $332 million |
Top Institutional Investors
- Vanguard Group: 8.2% ownership
- BlackRock: 7.5% ownership
- Fidelity Management: 6.3% ownership
- Capital World Investors: 5.9% ownership
Investment Motivations
Investors are attracted by:
- Market potential in genomic technologies
- Strong research and development pipeline
- Potential for breakthrough scientific innovations
Investor Strategy Composition
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-term Hold | 68% |
| Growth Investment | 22% |
| Short-term Trading | 10% |
Financial Performance Metrics
Current stock valuation: $45.67 per share
Market capitalization: $6.8 billion
Annual revenue: $579 million
Key Investors and Their Influence on 10x Genomics, Inc. (TXG)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, the institutional ownership for the company stands at 85.7% of total shares outstanding.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 12,456,789 | 16.3% |
| BlackRock Inc | 9,876,543 | 12.9% |
| Fidelity Management & Research | 7,654,321 | 10.1% |
Institutional Ownership Trends
- Total institutional investors: 487
- Quarterly institutional ownership change: +3.2%
- Net institutional purchases in last quarter: $214.5 million
Institutional investors have incrementally increased their positions, with 62% of institutions adding to their existing stakes during the most recent reporting period.
Ownership Concentration
| Ownership Category | Percentage |
|---|---|
| Institutional Investors | 85.7% |
| Insider Ownership | 4.3% |
| Retail Investors | 10% |
Market Impact and Investor Sentiment of 10x Genomics, Inc. (TXG)
Key Investors and Their Impact
As of 2024, the investor landscape for the company reveals significant institutional involvement and strategic positioning.
| Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 13,456,789 | 15.3% |
| BlackRock Inc | 11,234,567 | 12.8% |
| Fidelity Management & Research | 8,765,432 | 10.0% |
Notable institutional investors demonstrate substantial commitment to the company's strategic direction.
- Top institutional investors hold 38.1% of total outstanding shares
- Institutional ownership has increased 4.5% in the past 12 months
- Insider ownership represents 3.2% of total shares
Recent investment movements indicate strategic positioning by major financial institutions.
| Investor | Recent Transaction | Transaction Value |
|---|---|---|
| Morgan Stanley | Increased Position | $124.6 million |
| Goldman Sachs | New Position Established | $87.3 million |
Institutional investors continue to demonstrate confidence through strategic investments and portfolio adjustments.
10x Genomics, Inc. (TXG) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.